2 results
Approved WMOWill not start
To evaluate the safety, tolerability and efficacy of IZD334 to reduce CRP in cardiovascular high-risk patients.
Approved WMORecruiting
Study CA001-050 is a Phase 2 randomized, open label, multicenter clinical study designed to assess the safety and tolerability, of treatment with MS-986012 in combination with chemotherapy (carboplatin and etoposide) and nivolumab when administered…